• ShareThis
  • Print
  • Text Size


MannKind's Chairman and CEO Recognized as One of PharmaVOICE's "100 Most Inspiring People in the Life Sciences"
Veteran Entrepreneur is Honored for His Unparalleled Commitment to Medical Research
August 2010 -
MannKind Corporation announced that the company's chairman and CEO Alfred E. Mann has been named to PharmaVOICE's list of the "100 Most Inspiring People in the Life Sciences." Mr. Mann was recognized for his extraordinary leadership and passion in his lifelong roles as a scientist, inventor, entrepreneur and philanthropist, for which he has received more than 70 honors from the public and private sectors, including life achievement and humanitarian awards. He was nominated to the list by peers, colleagues and friends who have worked with him throughout his career and who describe him as "boundlessly visionary and persistent." Throughout Mr. Mann's nearly 60 years in the life sciences industry, the octogenarian billionaire has founded 17 companies, devoting his professional life to developing innovative medical products and technologies to satisfy the unmet needs of patients with health issues ranging from diabetes and heart disease to hearing impairment and chronic pain. More

MannKind Corporation Achieves All Milestones of Research Agreement with Multiple Myeloma Research Foundation to Develop New Therapy
March 2010 - The Multiple Myeloma Research Foundation (MMRF) and MannKind Corporation announced that MannKind has successfully achieved all milestones of a research agreement with MMRF to develop a novel, first-in-class inhibitor for the treatment of multiple myeloma. The MMRF awarded MannKind a $1 million grant through its 2007 Biotech Investment Award program, a multi-year, results-driven commitment to fund the development of innovative and effective treatments for multiple myeloma, based on clearly defined milestones. More

Frost & Sullivan Acknowledges MannKind for Entrepreneurial Company of the Year Award
March 2010 - Frost & Sullivan selected MannKind Corporation as the recipient of the prestigious 2010 North America Frost & Sullivan Entrepreneurial Company of the Year Award. In making this award, Frost & Sullivan lauded MannKind's growth strategy based on its innovative products and technologies. MannKind's lead investigational product AFREZZA® (insulin human [rDNA origin]) Inhalation Powder, is a novel, ultra rapid acting mealtime insulin therapy made using the company's proprietary Technosphere® formulation technology. The Technosphere technology can be applied to a wide range of drug delivery challenges and therapeutic areas, thus providing the company with a versatile asset for drug development. More

MannKind Wins Two "Facility of the Year 2010" Category Awards
January 2010 - MannKind Corporation announced that its commercial manufacturing facility in Danbury, Conn., custom-built for the production of its proprietary insulin therapy, has been awarded two "Facility of the Year 2010" category awards for process innovation and equipment innovation. For 2010, twenty-one companies from twelve countries were considered. MannKind's facility was the first in the history of the awards ever to win in two categories. More

Media Room

In the Media Center you will find fact sheets, videos and images

Learn More